We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+16.47%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.4B
AUM Growth
+$418M
Cap. Flow
+$336M
Cap. Flow %
23.99%
Top 10 Hldgs %
35.88%
Holding
162
New
35
Increased
43
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$36.7M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$30.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$26.7M
5
IMCR icon
Immunocore
IMCR
+$25.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24.4M
2
DVAX
Dynavax Technologies
DVAX
+$6.61M
3
BEAM icon
Beam Therapeutics
BEAM
+$2.58M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.54M
5
INBX icon
Inhibrx
INBX
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Technology 1.47%
3 Communication Services 1.22%
4 Real Estate 0.34%
5 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$5.93B
$15.7M 1.12%
628,609
+3,300
+0.5% +$80.4K
JAZZ icon
27
Jazz Pharmaceuticals
JAZZ
$16.7B
$15.6M 1.11%
140,000
– –
AVIR icon
28
Atea Pharmaceuticals
AVIR
$420M
$15.4M 1.1%
4,607,060
+130,319
+3% +$473K
CGEM icon
29
Cullinan Oncology
CGEM
$1.14B
$15.4M 1.1%
921,138
– –
META icon
30
Meta Platforms (Facebook)
META
$1.51T
$14.8M 1.06%
25,855
+14,459
+127% +$7.44M
RCKT icon
31
Rocket Pharmaceuticals
RCKT
$394M
$13.9M 0.99%
750,000
– –
ZYME icon
32
Zymeworks
ZYME
$1.67B
$13.8M 0.99%
1,100,000
– –
REPL icon
33
Replimune Group
REPL
$1.01B
$13.2M 0.94%
1,200,000
+394,560
+49% +$4.01M
RVNC
34
DELISTED
Revance Therapeutics, Inc.
RVNC
$13M 0.93%
2,500,000
+2,100,000
+525% +$10.4M
CRGX
35
DELISTED
CARGO Therapeutics
CRGX
$12.9M 0.92%
700,749
+128,052
+22% +$2.29M
TDOC icon
36
Teladoc Health
TDOC
$1.3B
$12.9M 0.92%
1,400,000
+400,000
+40% +$3.31M
NVAX icon
37
Novavax
NVAX
$1.31B
$12.6M 0.9%
+1,000,000
New +$12.9M
CRSP icon
38
CRISPR Therapeutics
CRSP
$5.17B
$12.5M 0.89%
266,500
-50,000
-16% -$2.54M
CRBP icon
39
Corbus Pharmaceuticals
CRBP
$190M
$12.4M 0.88%
+600,000
New +$30.7M
ACET icon
40
Adicet Bio
ACET
$74.7M
$11.8M 0.85%
513,560
– –
AZN icon
41
AstraZeneca
AZN
$250B
$11.7M 0.83%
75,000
– –
HRMY icon
42
Harmony Biosciences
HRMY
$2.24B
$11.2M 0.8%
281,200
– –
VNDA icon
43
Vanda Pharmaceuticals
VNDA
$302M
$11M 0.79%
2,353,307
+200,000
+9% +$1.07M
IMNM icon
44
Immunome
IMNM
$2.83B
$10.5M 0.75%
720,000
– –
CTMX icon
45
CytomX Therapeutics
CTMX
$754M
$9.22M 0.66%
7,811,760
+19,824
+0.3% +$25.2K
NUVB icon
46
Nuvation Bio
NUVB
$2.32B
$8.93M 0.64%
3,900,000
+148,136
+4% +$452K
ELAN icon
47
Elanco Animal Health
ELAN
$11.1B
$8.81M 0.63%
+600,000
New +$8.36M
HLVX
48
DELISTED
HilleVax
HLVX
$8.66M 0.62%
+4,920,000
New +$12.6M
OTLK icon
49
Outlook Therapeutics
OTLK
$191M
$8.33M 0.59%
1,559,560
-59,852
-4% -$438K
ONC
50
BeOne Medicines Ltd
ONC
$39.4B
$8.31M 0.59%
37,000
– –
1
2
3 4 5

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Tang Capital Management held 162 positions worth $1.4B, up 43% from $982M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tang Capital Management deployed $336M of net new capital in Q3 2024, opening 35 new positions and adding to 43 existing holdings. Its largest new stake was iTeos Therapeutics: 2,407,800 shares worth $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Dynavax Technologies, an estimated $6.61M trimmed.

  • Tang Capital Management's largest Q3 2024 buy was iTeos Therapeutics: 2,407,800 shares worth $24.6M.
  • Tang Capital Management added most to Aurinia Pharmaceuticals in Q3 2024, an estimated $27.6M increase.
  • Tang Capital Management's biggest Q3 2024 reduction was Dynavax Technologies, cutting an estimated $6.61M.
  • Tang Capital Management fully exited Eli Lilly in Q3 2024, selling an estimated $24.4M.
  • Tang Capital Management's ten largest holdings make up 36% of its $1.4B portfolio in Q3 2024.
  • Tang Capital Management opened 35 new positions and closed 8 in Q3 2024.
  • Tang Capital Management's portfolio value rose 43% quarter-over-quarter to $1.4B.

Based on Tang Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.